DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic StrokeBusiness Wire • 06/21/23
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of DirectorsBusiness Wire • 05/30/23
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial ResultsBusiness Wire • 05/15/23
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023Business Wire • 05/08/23
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial ResultsBusiness Wire • 03/28/23
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023Business Wire • 03/20/23
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare ConferenceBusiness Wire • 03/13/23
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of DirectorsBusiness Wire • 03/06/23
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial ResultsBusiness Wire • 11/09/22
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022Business Wire • 11/07/22
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare ConferenceBusiness Wire • 10/31/22
DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development OperationsBusiness Wire • 09/14/22
DiaMedica Therapeutics to Present at Lake Street's 6th Annual Best Ideas Growth ConferenceBusiness Wire • 09/06/22
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial ResultsBusiness Wire • 08/10/22
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022Business Wire • 08/04/22
DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022Business Wire • 08/01/22
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199Business Wire • 07/06/22
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022Business Wire • 05/25/22